Clinical Study

Mesenchymal Stromal Cells Do Not Increase the Risk of Viral Reactivation Nor the Severity of Viral Events in Recipients of Allogeneic Stem Cell Transplantation

Table 2

Viral reactivations details.

UPNVirusSampleDays from MSC infusionTreatmentOutcome

1EBVBlood100RituximabAlive, no GvHD
4CMV
EBV
Blood
Blood
13
40
Ganciclovir
Rituximab
Alive, no GvHD
7ADVBlood + stool7CidofovirAlive, no GvHD
9CMVBlood1GanciclovirDied on day +456 from SCT from sepsis
10 CMVBlood2Ganciclovir then FoscavirAlive, no GvHD
11ADVBlood + stool3CidofovirDied on day +90 from SCT from GvHD
13EBVBlood44RituximabAlive, no GvHD
14EBV CMVBlood
Blood + gut biopsy
1
7
Rituximab
Ganciclovir+ Foscavir
Died on day +129 from SCT from sepsis
15CMV
EBV
Blood
Blood
1
1
Ganciclovir
None
Died on day +168 from SCT from septic shock
16EBV
CMV
ADV
Blood
Blood + gut biopsy
Blood + gut biopsy
1
1
40
None
Ganciclovir + Foscavir
Cidofovir
Died on day +225 from SCT from GvHD
17CMVBlood31 GanciclovirDied on day +136 from SCT from disease recurrence

EBV: Epstein Barr Virus, CMV: Cytomegalovirus, ADV: Adenovirus, GvHD: Graft versus Host Disease, and SCT: stem cellstransplantation.